Melasma is acquired light to dark-
Conditions
Interventions
combination of
-
0.15%thiamidol : tyrosinase inhibitor and
-
hyaluronic acid ,0.15%thiamidol : tyrosinase inhibitor,humectant
combination 0.15%thiamidol and hyaluronic acid,0.15%thiamidol,hyaluronic acid
Sponsors
Faculty of medicine, Thammasat university
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Women 18-65 years of age having general good health 2.Fitzpatrick skin type II-IV 3.Individuals with any types of melasma 4.Individuals who use sunscreen daily with at least SPF30 5.Individuals that willing to provide written informed consent and are able to read, speak, write, and understand Thai. 6.Individuals of child-bearing potential who are willing to take a urine pregnancy test prior to study enrollment and when deemed appropriate by the investigator and/or sponsor 7. Individuals of child-bearing potential who use an acceptable method of contraception throughout the study and must be on a stable use for 3 months prior to study enrollment and must not alter their use, including dose or regimen for the duration of the study 8. Willing to withhold all facial treatments during the course of the study, including botulinum toxin, injectable fillers, microdermabrasions, intense pulse light, peels, laser treatment and thread 9. Willing to co-operate and participate by following study requirements for the duration of the study and to report any changes in health status or medications, adverse event symptoms, or reactions immediately
Exclusion criteria
Exclusion criteria: 1. History of laser resurfacing procedures, deep skin peel, botulinum toxin, or injection with a dermal filler, or cosmetic procedures on the face within 6 months prior to enrollment. 2. Use of depigmenting products within 2 months prior to enrollment. 3. Use of any topical medications on the face for the treatment of hyperpigmented lesions or other conditions, or use of photosensitizing medication or procedures, bleaching products on the face, UV light therapy, topical prescription treatments, transamin, glutathione, vitamin or topical tretinoin on the face, or Use of acitretin, isotretinoin, systemic retinoids, methotrexate, or photoallergic, phototoxic, or photo-sensitizing drugs fewer than 30 days prior to the study entry. 4. Facial microdermabrasion treatment within 6 weeks prior to study entry. 5. Known allergies to facial skin care products. 6. Pregnancy or nursing or planning to become pregnant during the study according to subject self-report, including those who are not using an acceptable method of contraception throughout the study. 7. History of skin cancer. 8. A health condition and/or pre-existing or dormant dermatologic disease on the face (e.g., psoriasis, rosacea, acne, eczema, seborrheic dermatitis, severe excoriations) that the investigator deems inappropriate for participation or could interfere with the outcome of the study. 9. History of immunosuppression/immune deficiency disorders, including HIV infection or acquired immunedeficiency syndrome, or currently using immunosup- pressive medications and/or radiation as determined by study documentation. 10. Uncontrolled disease such as asthma, diabetes, hyper- tension, hyperthyroidism, or hypothyroidism. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet or medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| melanin average level 0,2,4,8,12 weeks antera | — |
Secondary
| Measure | Time frame |
|---|---|
| modified MASI score and TEWL 0,2,4,8,12 wk by investigator and tewameter | — |
Countries
Thailand
Contacts
Public ContactWareeporn Disphanurat
Faculty of medicine, Thammasat university
Outcome results
None listed